Immunotherapy and radiation therapy: Considerations for successfully combining radiation into the paradigm of immuno-oncology drug development

Elad Sharon, Mei-Yin Polley, Michael B. Bernstein, Mansoor Ahmed

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

As the immunotherapy of cancer comes of age, adding immunotherapeutic agents to radiation therapy has the potential to improve the outcomes for patients with a wide variety of malignancies. Despite the enormous potential of such combination therapy, laboratory data has been lacking and there is little guidance for pursuing novel treatment strategies. Animal models have significant limitation in combining radiation therapy with immunotherapy and some of the limitations of preclinical models are discussed in this article. In addition to the preclinical challenges, radiation therapy and immunotherapy combinations may have overlapping toxicities, and for both types of therapy, early and late manifestations of toxicity are possible. Given these risks, special attention should be given to the design of the specific Phase I clinical trial that is chosen. In this article, we describe several Phase I design possibilities that may be employed, including the 3 + 3 design (also known as the cohort of 3 design), the continual reassessment method (CRM), and the time-to-event continual reassessment method (TITE-CRM). Efficacy end points for further development of combination therapy must be based on multiple factors, including disease type, stage of disease, the setting of therapy and the goal of therapy. While the designs for future clinical trials will vary, it is clear that these two successful modalities of therapy can and should be combined for the benefit of cancer patients.

Original languageEnglish (US)
Pages (from-to)252-257
Number of pages6
JournalRadiation Research
Volume182
Issue number2
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Immunotherapy
radiation therapy
therapy
drugs
Radiotherapy
Radiation
radiation
Pharmaceutical Preparations
toxicity
Therapeutics
cancer
animal models
Neoplasms
Clinical Trials, Phase I
Animal Models
Clinical Trials

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Biophysics
  • Radiation

Cite this

Immunotherapy and radiation therapy : Considerations for successfully combining radiation into the paradigm of immuno-oncology drug development. / Sharon, Elad; Polley, Mei-Yin; Bernstein, Michael B.; Ahmed, Mansoor.

In: Radiation Research, Vol. 182, No. 2, 01.01.2014, p. 252-257.

Research output: Contribution to journalArticle

@article{49e511d1c2f649c2919cc1a56bc6575d,
title = "Immunotherapy and radiation therapy: Considerations for successfully combining radiation into the paradigm of immuno-oncology drug development",
abstract = "As the immunotherapy of cancer comes of age, adding immunotherapeutic agents to radiation therapy has the potential to improve the outcomes for patients with a wide variety of malignancies. Despite the enormous potential of such combination therapy, laboratory data has been lacking and there is little guidance for pursuing novel treatment strategies. Animal models have significant limitation in combining radiation therapy with immunotherapy and some of the limitations of preclinical models are discussed in this article. In addition to the preclinical challenges, radiation therapy and immunotherapy combinations may have overlapping toxicities, and for both types of therapy, early and late manifestations of toxicity are possible. Given these risks, special attention should be given to the design of the specific Phase I clinical trial that is chosen. In this article, we describe several Phase I design possibilities that may be employed, including the 3 + 3 design (also known as the cohort of 3 design), the continual reassessment method (CRM), and the time-to-event continual reassessment method (TITE-CRM). Efficacy end points for further development of combination therapy must be based on multiple factors, including disease type, stage of disease, the setting of therapy and the goal of therapy. While the designs for future clinical trials will vary, it is clear that these two successful modalities of therapy can and should be combined for the benefit of cancer patients.",
author = "Elad Sharon and Mei-Yin Polley and Bernstein, {Michael B.} and Mansoor Ahmed",
year = "2014",
month = "1",
day = "1",
doi = "10.1667/RR13707.1",
language = "English (US)",
volume = "182",
pages = "252--257",
journal = "Radiation Research",
issn = "0033-7587",
publisher = "Radiation Research Society",
number = "2",

}

TY - JOUR

T1 - Immunotherapy and radiation therapy

T2 - Considerations for successfully combining radiation into the paradigm of immuno-oncology drug development

AU - Sharon, Elad

AU - Polley, Mei-Yin

AU - Bernstein, Michael B.

AU - Ahmed, Mansoor

PY - 2014/1/1

Y1 - 2014/1/1

N2 - As the immunotherapy of cancer comes of age, adding immunotherapeutic agents to radiation therapy has the potential to improve the outcomes for patients with a wide variety of malignancies. Despite the enormous potential of such combination therapy, laboratory data has been lacking and there is little guidance for pursuing novel treatment strategies. Animal models have significant limitation in combining radiation therapy with immunotherapy and some of the limitations of preclinical models are discussed in this article. In addition to the preclinical challenges, radiation therapy and immunotherapy combinations may have overlapping toxicities, and for both types of therapy, early and late manifestations of toxicity are possible. Given these risks, special attention should be given to the design of the specific Phase I clinical trial that is chosen. In this article, we describe several Phase I design possibilities that may be employed, including the 3 + 3 design (also known as the cohort of 3 design), the continual reassessment method (CRM), and the time-to-event continual reassessment method (TITE-CRM). Efficacy end points for further development of combination therapy must be based on multiple factors, including disease type, stage of disease, the setting of therapy and the goal of therapy. While the designs for future clinical trials will vary, it is clear that these two successful modalities of therapy can and should be combined for the benefit of cancer patients.

AB - As the immunotherapy of cancer comes of age, adding immunotherapeutic agents to radiation therapy has the potential to improve the outcomes for patients with a wide variety of malignancies. Despite the enormous potential of such combination therapy, laboratory data has been lacking and there is little guidance for pursuing novel treatment strategies. Animal models have significant limitation in combining radiation therapy with immunotherapy and some of the limitations of preclinical models are discussed in this article. In addition to the preclinical challenges, radiation therapy and immunotherapy combinations may have overlapping toxicities, and for both types of therapy, early and late manifestations of toxicity are possible. Given these risks, special attention should be given to the design of the specific Phase I clinical trial that is chosen. In this article, we describe several Phase I design possibilities that may be employed, including the 3 + 3 design (also known as the cohort of 3 design), the continual reassessment method (CRM), and the time-to-event continual reassessment method (TITE-CRM). Efficacy end points for further development of combination therapy must be based on multiple factors, including disease type, stage of disease, the setting of therapy and the goal of therapy. While the designs for future clinical trials will vary, it is clear that these two successful modalities of therapy can and should be combined for the benefit of cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=84905753033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905753033&partnerID=8YFLogxK

U2 - 10.1667/RR13707.1

DO - 10.1667/RR13707.1

M3 - Article

C2 - 25003314

AN - SCOPUS:84905753033

VL - 182

SP - 252

EP - 257

JO - Radiation Research

JF - Radiation Research

SN - 0033-7587

IS - 2

ER -